273 related articles for article (PubMed ID: 30302397)
1. Emerging role of precision medicine in biliary tract cancers.
Bogenberger JM; DeLeon TT; Arora M; Ahn DH; Borad MJ
NPJ Precis Oncol; 2018; 2():21. PubMed ID: 30302397
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.
Turkes F; Carmichael J; Cunningham D; Starling N
Gastroenterol Res Pract; 2019; 2019():7698786. PubMed ID: 31929787
[TBL] [Abstract][Full Text] [Related]
3. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
5. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
6. Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology.
Manne A; Woods E; Tsung A; Mittra A
Front Oncol; 2021; 11():768009. PubMed ID: 34868996
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
9. The Role of HER2 Status in the Biliary Tract Cancers.
Ayasun R; Ozer M; Sahin I
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174094
[TBL] [Abstract][Full Text] [Related]
10. Precision Medicine in Biliary Tract Cancer.
Scott AJ; Sharman R; Shroff RT
J Clin Oncol; 2022 Aug; 40(24):2716-2734. PubMed ID: 35839428
[TBL] [Abstract][Full Text] [Related]
11. Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
Marin JJG; Prete MG; Lamarca A; Tavolari S; Landa-Magdalena A; Brandi G; Segatto O; Vogel A; Macias RIR; Rodrigues PM; Casta A; Mertens J; Rodrigues CMP; Fernandez-Barrena MG; Da Silva Ruivo A; Marzioni M; Mentrasti G; Acedo P; Munoz-Garrido P; Cardinale V; Banales JM; Valle JW; Bridgewater J; Braconi C;
Br J Cancer; 2020 Sep; 123(7):1047-1059. PubMed ID: 32694694
[TBL] [Abstract][Full Text] [Related]
12. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
[TBL] [Abstract][Full Text] [Related]
13. Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors.
Pezzicoli G; Triggiano G; Sergi MC; Mannavola F; Porta C; Tucci M
Am J Transl Res; 2021; 13(8):8598-8610. PubMed ID: 34539982
[TBL] [Abstract][Full Text] [Related]
14. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
[TBL] [Abstract][Full Text] [Related]
15. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; ChilĂ G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer.
Wang Y; Chen T; Li K; Mu W; Liu Z; Shi A; Liu J; Zhao W; Lian S; Huang S; Pan C; Zhang Z
Front Oncol; 2021; 11():777617. PubMed ID: 34778094
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of biliary tract cancer: a target rich disease.
Jain A; Javle M
J Gastrointest Oncol; 2016 Oct; 7(5):797-803. PubMed ID: 27747093
[TBL] [Abstract][Full Text] [Related]
18. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D; Ferté C
Eur J Cancer; 2017 Aug; 81():161-173. PubMed ID: 28628842
[TBL] [Abstract][Full Text] [Related]
19. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer.
Canale M; Monti M; Rapposelli IG; Ulivi P; Sullo FG; Bartolini G; Tiberi E; Frassineti GL
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830826
[TBL] [Abstract][Full Text] [Related]
20. Translating cancer genomics for precision oncology in biliary tract cancers.
Haber PK; Sia D
Discov Med; 2019; 28(155):255-265. PubMed ID: 32053766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]